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Summary.-Human breast cancer cells were adapted to chemically defined medium
in order to recover naturally shed glycoproteins. Sephadex G-150 chromatography
ofthese glycoproteins revealed 1 major and 2 minor peaks. When the cells were grown
in the presence of 3H-leucine, the radioactive shed proteins had a Sephadex profile
identical to the unlabelled shed glycoproteins. PAGE analysis of these proteins
showed 5 major bands. Antigenically similar proteins were found in the serum of
female nude mice bearing BOT-2 tumours, but not in controls.
THE ESCAPE of tumours from host
immunological defence mechanisms has
only recently begun to be associated with
the tumour-cell membrane and, specific-
ally, the glycoproteins on the exterior
surface. Increasing evidence suggests that
metastatic tumours synthesize and release
antigenic membrane-associated proteins
which circulate in afree state or complexed
with host immunoglobulins. However, the
synthesis and release of membrane pro-
teins is not an exclusive trait of neoplastic
cells, for Ruoslahti and Vaheri (1974) have
shown that membrane proteins are shed
from normal human fibroblasts and enter
the blood of the host. Alexander (1974)
pointed out that the shedding of surface
antigens may also be a characteristic of
embryonic as well as malignant cells. He
suggested that shed antigens caused the
immunological blocking in natural allo-
graft situations such as mammalian preg-
nancy or successful neoplastic processes.
Studies by Thomson and Alexander (1973)
on the MCI rat sarcoma indicated that the
embryonic types of protein were re-
expressed on the tumour-cell membrane
simultaneously with tumour-specific trans-
plantation antigens. Similar findings in
human tumours were demonstrated by
Hollinshead et al. (1972), who showed that
human colonic tumours expressed carcino-
embryonic antigen at the same time as
tumour-specific antigens. Kim et al. (1975)
suggested that the ability of cancer cells
to survive and metastasize is directly
attributable to antigen shedding.
The above data suggest that living cells
shed proteins, and that in neoplasia the
elaborated proteins may block cytotoxic
activities and effect an active immuno-
logical escape mechanism.
In a previous report, Lerner et al.
(1978) demonstrated that the BOT-2
human mammary carcinoma cell-line pro-
duced distinct proteins which were loosely
bound to the cells. These proteins had a
molecular weight in the range of 100,000
daltons, as estimated by gel filtration and
PAGE analysis, and reacted with anti-
bodies from breast-cancer patients. This
study also suggested that BOT-2 human
mammary carcinoma cells naturally re-
leased glycoproteins into the medium in
sufficient quantity to be recovered. Nord-
quist et al. (1977a) showed the remarkable
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fluidity ofthe living BOT-2 cell membranes
by demonstrating antigen shedding in
response to antibodies of breast cancer
patients. Further work in the same system
by Anglin et al. (1977) revealed that some
of the glycoproteins released by BOT-2
cells had blood-group-like activity.
The present work was designed to: (1)
evaluate the shedding of glycoproteins by
BOT-2 cell cultures in serum-free medium,
(2) isolate and partially characterize the
glycoproteins shed in vitro by BOT-2 cells,
and (3) demonstrate the active release of
these glycoproteins into the circulation of
animals bearing BOT-2 tumours.
MATERIALS AND METHODS
BOT-2 cells were grown under conditions
previously described by Nordquist et al.
(1975) and trypsinized to split 106 cells per
75-cm2 flask. When the cells attached to the
substrate, the medium containing heat-
denatured foetal calfserum wras replaced with
10 ml of Eagle's minimal essential medium
without foetal calf serum, but enriched with
500 mg0' glucose. This medium was renewed
at 3-day intervals, the 4th interval medium
collected and lyophilized immediately. When
dry, the spent medium was reconstituted to
one-tenth the original volume and exhaustive-
ly dialysed against phosphate-buffered saline
PBS, pH 7-2. For radioactive-incororporation
studies, cells were grown for 3 days in the
same medium containing 10 1tCi/ml of 3H-
leucine (sp. act. 35 Ci/mmol) and dialysed and
lyophilized. These samples were then applied
to a Sephadex G-150 column (48 x 2 7 cm)
equilibrated at 4°C with PBS. Fractions of
3 ml were collected and either the absorbency
at 280 nm or the radioactivity was deter-
mined. Contiguous fractions of absorbing
material were pooled, dialysed against several
changes of distilled water, and lyophilized.
The lyophilized samples were dissolved in
PBS and analysed by polyacrylamide-gel
electrophoresis (PAGE). Gels were 7 x 120 mm
and contained 900 acrylamide with a 3.500
acrylamide stacker. Gel buffer (pH 83)
consisted of 0-025 M Tris, 0-19 M glycine.
Samples, in 10% glycerol, were applied to the
gels and electrophoresed at 3 mA/gel until the
tracking dye was at the bottom of the gel.
Gels were stained for 2 h at 37°C in 0-3%
Coomassie brilliant blue in methanol acetic
acid : water (50 : 7 : 43) and destained by
diffusion in methanol : acetic acid : water
(10 : 7 : 83). To locate protein bands, de-
stained gels -were scanned at 550 nm in a
Gilford spectrophotometer equipped with a
20 cm linear transport.
In vivo studies wxere accomplished by
injecting 106 BOT-2 cells s.c. into female
athymic nude mice. When tumours were
palpable, the animal was bled from the retro-
orbital sinus and the serum collected. Controls
for this experiment were nude mice with
growing human melanoma or human mono-
cytie leukemia, and untreated nude mice. The
serum was loaded in a 10% agarose double-
diffusion plate and reacted against a rabbit
antiserum prepared against BOT-2 cells.
Antiserum against BOT-2 cells (Lerner et
at., 1978) w-as prepared by injecting rabbits
writh 106 cells in Freund's complete adjuvant.
The resulting antiserum was chromatograph-
ed on DEAE-Sephadex to isolate the gamma
G fraction, which w%as fully absorbed with
cross-linked foetal calf serum, acetone
extracts, human tissue, and packed HeLa
cells. Rabbit anti-BOT-2 serum reacted only
against BOT-2 cells and human breast tum-
our tissue. No fluorescence was observed
when the serum wvas tested against HeLa
cells, human melanoma or alveolar carcinoma
cells or normal ductal cells within a breast-
tissue specimen.
RESULTS
The BOT-2 mammary carcinoma cells
grew well in the serum-free medium but
could not be trypsinized without destruc-
tion of most of the cells. When the spent
medium was collected (at 3-day intervals)
and pooled from 10 confluent 75 cm2
flasks, -3 mg of protein could be re-
covered. The same monolayer ofcells could
then be re-fed for a subsequent collection
of antigens. After lyophilization and
dialysis, both the labelled and unlabelled
shed proteins were chromatographed on
Sephadex G-150. The results, shown in Fig.
1, indicated that 1 major and 2 minor
protein peaks were present in the BOT-2
cell preparation. Minor protein peaks
occurred at the column void volume (Frac-
tion 20) and at Fraction 68. The bulk of
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FiG. 1. Sephadex G-150 separation profiles of naturally shed proteins from BOT-2 cells. The growth
medium from BOT-2 cells grown with and without 3H-leucine was prepared and separated as
described under MATERIALS AND METHODS. , absorbency profile of growth medium; - - - -,
radioactive profile of growth medium from cells grown with 3H-leucine. Arrow ( 4 ) indicates the
peak which was analysed by PAGE.
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FIG. 2.-Absorbency tracing of PAGE
analysis of BOT-2 cell proteins separated
on Sephadex G-150. The major (middle)
protein peak obtained from Sephadex G-
150 separation of BOT-2 naturally shed
proteins was analysed by PAGE as des-
cribed under MATERIALS AND METHODS.
The arrow () indicates the band with
the same mobility as bovine lactalbumin.
the BOT-2 shed proteins eluted around
Fraction 40, which migrated slightly
ahead of bovine serum albumin (67,000
daltons, Fraction 50). The separation
profile of the BOT-2 growth medium
corresponded exactly to the separation
profile of the 3H-leucine-labelled proteins.
The major (2nd) G-150 peak ofBOT-2 shed
proteins was analysed by PAGE under
non-denaturing conditions. Gel profiles
revealed 1 fast-migrating intensely-stained
band and 4 slower-migrating lighter-
stained bands (Fig. 2). The large fast-
migrating band migrated to the same
position on the gels as commercial purified
bovine lactalbumin.
The injection of female nude mice with
BOT-2 cells produced large local and
metastatic tumours. No tumours were
produced in male mice. When the serum
from these BOT-2 tumour-bearing mice
was assayed by immunoprecipitation for
circulating BOT-2 antigen, it was found in
every case. No similar antigens were found
in nude mice bearing human malignant
melanoma or human monocytic leukemia,
or in control nude mice.
DISCUSSION
The establishment of the BOT-2 human
breast cancer cell line was reported by
Nordquist et al. (1975). Further investiga-
tion demonstrated that this cell line had
plasma-membrane-associated antigens
that bound antibodies from the sera of
breast-cancer patients in 46% of the cases
tested (Nordquist et al., 1977b). Lerner et
al. (1978) showed that these antigens could
be extracted from the breast-cancer cells
and separated from most of the con-
taminating calf-serum proteins in the
culture medium. We felt that it might be
possible to obtain very pure preparations
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of released glycoproteins, if one could
adapt the human mammary carcinoma
cells to culture in defined medium without
the contaminating proteins in foetal calf
serum. When the tumour cells were
successfully adapted to culture in chemi-
cally defined medium, a considerable
amount of antigenic material was shed by
the BOT-2 cells. Some ofthis material had
activities similar to the blood-group anti-
gens M, N, T, and Tn (Anglin et al., 1977).
Gel-filtration and PAGE profiles of the
antigen recovered from chemically defined
medium are very similar to the patterns of
extracted BOT-2 antigens (Lerner et al.,
1978) with the exception that non-anti-
body reacting peaks were greatly
diminished.
The question then arose, was this a
product that was unique to tissue-culture
cells, or was it the result of protein libera-
tion from dying cell populations? Two
methods were used to answerthis question.
Firstly, the cells weregrowninthepresence
of 3H-leucine, which demonstrated the
active synthesis and release of these
proteins. Secondly, the cells were injected
into female athymic nude mice, where
large tumours which shed detectable
amounts of anti-BOT antibody-reactive
material were produced. The finding that
BOT-2 tumours were not produced in male
nude mice suggests hormone dependence,
although assays for oestrogen-binding
proteins in BOT-2 cells havebeennegative.
Our results indicate that antigen shed-
ding is a natural phenomenon of breast
tumour cells in vivo as well as in vitro.
Furthermore, preliminary radioimmuno-
assay studies indicate that antigenically
similar proteins are also present in the
serum of some breast-cancer patients with
widespread metastatic disease. Recent
work in the field of tumour immunology
has strongly suggested that tumour cell-
surface glycoproteins play a significant
role in immunological escape. The results
of our work support the principle that in
human breast cancer some tumours may
escape the immune system by: (1) mimick-
ing blood-group antigens on the tumour
cell surfaces and (2) producing large
amounts of blocking antigen that are shed
into the host's circulation.
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